Ambalal Sarabhai Enterprises Past Earnings Performance
Past criteria checks 4/6
Ambalal Sarabhai Enterprises's earnings have been declining at an average annual rate of -13.6%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 4.6% per year. Ambalal Sarabhai Enterprises's return on equity is 8.9%, and it has net margins of 6.8%.
Key information
-13.6%
Earnings growth rate
-13.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 4.6% |
| Return on equity | 8.9% |
| Net Margin | 6.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ambalal Sarabhai Enterprises makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,836 | 124 | 295 | 0 |
| 30 Jun 24 | 1,789 | 109 | 287 | 0 |
| 31 Mar 24 | 1,743 | 57 | 279 | 0 |
| 31 Dec 23 | 1,655 | 29 | 288 | 0 |
| 30 Sep 23 | 1,577 | 47 | 273 | 0 |
| 30 Jun 23 | 1,627 | 46 | 260 | 0 |
| 31 Mar 23 | 1,710 | 114 | 260 | 0 |
| 31 Dec 22 | 1,810 | 132 | 256 | 0 |
| 30 Sep 22 | 1,888 | 137 | 261 | 0 |
| 30 Jun 22 | 1,977 | 222 | 248 | 0 |
| 31 Mar 22 | 1,976 | 472 | 267 | 0 |
| 31 Dec 21 | 1,923 | 552 | 332 | 0 |
| 30 Sep 21 | 1,952 | 537 | 338 | 0 |
| 30 Jun 21 | 1,797 | 550 | 279 | 0 |
| 31 Mar 21 | 1,652 | 294 | 341 | 0 |
| 31 Dec 20 | 1,537 | 267 | 285 | 0 |
| 30 Sep 20 | 1,394 | 251 | 281 | 0 |
| 30 Jun 20 | 1,293 | 144 | 270 | 0 |
| 31 Mar 20 | 1,335 | 141 | 279 | 0 |
| 31 Dec 19 | 1,397 | 23 | 265 | 0 |
| 30 Sep 19 | 1,447 | 45 | 273 | 0 |
| 30 Jun 19 | 1,468 | 46 | 276 | 0 |
| 31 Mar 19 | 1,519 | 42 | 280 | 0 |
| 31 Dec 18 | 1,489 | 71 | 289 | 0 |
| 30 Sep 18 | 1,417 | 72 | 290 | 0 |
| 30 Jun 18 | 1,317 | 44 | 297 | 0 |
| 31 Mar 18 | 1,250 | 13 | 295 | 0 |
| 31 Mar 17 | 1,339 | -182 | 319 | 0 |
| 31 Mar 16 | 1,321 | 481 | 344 | 0 |
| 31 Mar 15 | 1,245 | -67 | 307 | 0 |
| 31 Mar 14 | 1,047 | -202 | 408 | 1 |
Quality Earnings: 500009 has high quality earnings.
Growing Profit Margin: 500009's current net profit margins (6.8%) are higher than last year (3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 500009's earnings have declined by 13.6% per year over the past 5 years.
Accelerating Growth: 500009's earnings growth over the past year (163.9%) exceeds its 5-year average (-13.6% per year).
Earnings vs Industry: 500009 earnings growth over the past year (163.9%) exceeded the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: 500009's Return on Equity (8.9%) is considered low.